(iv) Experimental and translational studies suggest that either genetic manipulation or pharmacological inhibition of HIF1α and HIF2α in both adipose tissue and small intestine can ameliorate obesity-associated metabolic diseases ([42], and references therein). The gene discussed is HIF1A; the disease is Other metabolic disease.